Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) reports a corporate governance event dated March 23, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of two directors from the Board of Directors. Dr. Jonathan Goldman and Mitchell Chan have notified the Company of their decision not to stand for re-election at the 2026 Annual Meeting of Stockholders. Both directors will continue to serve until the meeting concludes. The filing explicitly states these departures are not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are disclosed in this document other than the standard transition of board membership.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the 2026 Annual Meeting.
- Confirm the date and agenda for the 2026 Annual Meeting of Stockholders.
- Review subsequent filings for any new director nominations to replace the departing members.
- Check for any related proxy statements detailing the rationale for the board changes.